Pages that link to "Q33842859"
Jump to navigation
Jump to search
The following pages link to Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer (Q33842859):
Displaying 50 items.
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer (Q26746209) (← links)
- Adoptive immunotherapy against ovarian cancer (Q26748905) (← links)
- Cancer stem cells and immunoresistance: clinical implications and solutions (Q26769757) (← links)
- Melanoma: oncogenic drivers and the immune system (Q26775598) (← links)
- Engineering opportunities in cancer immunotherapy (Q26776373) (← links)
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators (Q26782799) (← links)
- Human Cancer Immunotherapy with PD-1/PD-L1 Blockade (Q26786108) (← links)
- Molecular and cellular insights into T cell exhaustion (Q26800047) (← links)
- Overcoming T cell exhaustion in infection and cancer (Q26829885) (← links)
- Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer (Q26996829) (← links)
- Primer on tumor immunology and cancer immunotherapy (Q27001126) (← links)
- Novel immunotherapies for hematologic malignancies (Q27004436) (← links)
- Tumor infiltrating lymphocytes in ovarian cancer (Q27021878) (← links)
- Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer (Q27022761) (← links)
- Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors (Q27350034) (← links)
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy (Q28066199) (← links)
- Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer (Q28066486) (← links)
- Recent Advances in Immunotherapy in Metastatic NSCLC (Q28069323) (← links)
- PD-1 and its ligands are important immune checkpoints in cancer (Q28069485) (← links)
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations (Q28075712) (← links)
- Immune checkpoint therapy for pancreatic cancer (Q28078390) (← links)
- Targeted immune therapy of ovarian cancer (Q28082828) (← links)
- Immune checkpoint blockade: a common denominator approach to cancer therapy (Q28083981) (← links)
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade (Q28298214) (← links)
- Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy (Q28394869) (← links)
- T cell exhaustion (Q29620463) (← links)
- Antibody Therapies in Cancer (Q31104000) (← links)
- Checkpoint inhibitors in hematological malignancies (Q33651495) (← links)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (Q33689478) (← links)
- Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade (Q33714165) (← links)
- Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets (Q33731047) (← links)
- At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy (Q33732329) (← links)
- Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia (Q33815992) (← links)
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells (Q33833475) (← links)
- Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients (Q33885996) (← links)
- Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis (Q34026088) (← links)
- Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization (Q34162609) (← links)
- Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression (Q34240499) (← links)
- Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape (Q34241893) (← links)
- PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. (Q34283708) (← links)
- Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers (Q34472941) (← links)
- Combination cancer immunotherapy and new immunomodulatory targets (Q34487698) (← links)
- Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity (Q34495723) (← links)
- Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes (Q34548226) (← links)
- Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. (Q34658452) (← links)
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. (Q34809019) (← links)
- PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation (Q34996125) (← links)
- Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer (Q35032491) (← links)
- Past, present and future targets for immunotherapy in ovarian cancer (Q35034010) (← links)
- Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer (Q35058278) (← links)